Logotype for InnovAge Holding Corp

InnovAge (INNV) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for InnovAge Holding Corp

Q3 2026 earnings summary

28 Aug, 2026

Executive summary

  • Fiscal Q3 2026 delivered a 15.5% year-over-year revenue increase to $251.9 million, with $61 million center-level contribution margin and $30.5 million adjusted EBITDA, serving about 8,050 participants across 20 centers in six states.

  • Year-to-date performance led to raised fiscal 2026 guidance for both revenue and adjusted EBITDA, reflecting improved operating execution and benefits from prior investments.

  • Investments in clinical teams, technology (including AI), and new centers, especially in Florida, are driving operational improvements and future growth.

  • Focus remains on quality, participant outcomes, and sustainable long-term performance, despite ongoing labor shortages, wage pressures, and regulatory challenges.

  • Ongoing legal and regulatory matters, including litigation and settlements, significantly impacted expenses and net loss.

Financial highlights

  • Total revenue for Q3 FY26 was $251.9 million, up 15.5% year-over-year and 5.1% sequentially, with nine-month revenue at $727.8 million, up 15.1%.

  • Center-level contribution margin rose to $61 million (24.2% of revenue), up from $40.7 million (18.7%) in Q3 FY25.

  • Adjusted EBITDA was $30.5 million (12.1% margin), up from $10.8 million (4.9%) in Q3 FY25; nine-month adjusted EBITDA was $70.3 million (9.7% margin).

  • Net loss widened to $29.9 million from $11.1 million in Q3 FY25, mainly due to increased litigation liability; net loss for nine months was $10.8 million.

  • Cash and equivalents at quarter-end were $95.5 million, with $43.1 million in short-term investments and $69.4 million in total debt.

Outlook and guidance

  • Fiscal 2026 revenue guidance raised to $950–$975 million and adjusted EBITDA to $85–$90 million.

  • Ending census expected between 7,900 and 8,100 participants; member months projected at 92,900–95,700.

  • De novo center losses for FY26 anticipated at $11.5–$13.5 million.

  • Fiscal 2027 expected to face more modest Medicare and Medicaid rate increases (Medicare 1.5–2%), creating top-line and margin pressure, especially in Colorado and California.

  • Plans to invest in operational initiatives, compliance, and participant growth and retention.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more